Why Some Of You With Hep C Will Loose Your Mmj Privilages In The Future!

[mrd]

Ok I am playing with your minds . You theoretically could loose your privaleges but for all the right reasons!

 

Pharmasset Rises After Hepatitis-C Drug Shows 100% Cure Rate in Trial

Q

By Elizabeth Lopatto - Nov 7, 2011 9:08 AM ET

 

inShare

More Print Email

Pharmasset Inc. (VRUS) rose as much as 16 percent in early trading after the company said its experimental drug for treating hepatitis C cured all patients in a study.

Shares of the Princeton, New Jersey-based company gained 8.6 percent to $74.83 at 8:03 a.m. New York time, before the market opened. They earlier rose as high as $80.

All 40 patients who received Pharmasset’s experimental PSI- 7977 drug were responsive after 12 weeks, the company said yesterday the annual meeting of the American Association for the Study of Liver Diseases in San Francisco. About half the patients had been followed up to 24 works, and they were all cured. There were no significant adverse events.

“Although patient numbers are small, we believe the results are extremely impressive,” wrote Brian Abrahams of Wells Fargo Securities in a note to investors today.

The drug was tested in combination with ribavirin, a medication currently used in treating the disease, in patients with hepatitis C genotypes 2 and 3. Genotype 1 is most common and hardest to treat.

There were four groups in the study: Those who were treated with no interferon and those who received four weeks, eight weeks and 12 weeks of it, according to the data. The study was initiated to see the shortest duration of interferon, which is injected, required for a response.

On Nov. 1, Pharmasset announced it began a phase 3 clinical trial of the drug in combination with ribavirin, without interferon. That would be an all-oral regimen to treat hepatitis C.

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

 

mod fixed title

[LongHairBri]

teriffic news!!

[Willy]

that would be nice so how long will i be dead before they release the medication to the public..

[mrd]

About 20 minutes. Right after your heart attack, after learning you won the lottery! Lucky guy!

 

You must take cynical pills. I can't imagine how pissed off your going to be if they ever cure cancer. I am sure you like many others have suffered with the illness, but this is good news. It is the type of drug trial that gets fast tracked. Notice the statement that there were no adverse reactions. Best of luck to you.

 

 

that would be nice so how long will i be dead before they release the medication to the public..

[solabeirtan]

Great news ! Thanks for the update mrd.

 

The most important part of this test will be in the next six months. To see if the Virus comes back or not.

 

We'll keep our fingers crossed.

[newbie313]

Great news!!!

[mrd]

It should be noted that they did not test it yet on the type one genotype which the article states is the most prevalent. We will have to see what comes up. Still for all you with the illness this is really good.

[trix]

Yep I get something called the "Bleeders digest" & "The Artery" The cancer center sends me them and I meant to post the article when I saw it Though the site was haveing some issues at that time. Here is a link/article from business wire Sept. 21, 2011

 

http://www.businesswire.com/news/home/20110920007352/en/Treatment-Hepatitis-Helps-Boost-Cure-Rate

 

New Treatment for Hepatitis C Helps Boost Cure Rate

HOUSTON--(BUSINESS WIRE)--The Methodist Hospital in Houston is excited to share significant news for patients who need treatment for hepatitis C genotype 1, a viral infection that causes liver inflammation that can lead to diminished liver function or symptoms for liver failure. Two new antiviral drugs recently approved by the Food and Drug Administration (FDA), Victrelis and Incivek, when taken with standard hepatitis C treatment drugs interferon and ribavirun, cured 65 percent to 75 percent of people with hepatitis C in clinical trials. “Two decades ago the cure rate for hepatitis C genotype 1 patients was about 6 percent, so this is a 10 times increase,” notes Dr. Howard Monsour, Chief of Hepatology at The Methodist Hospital in Houston. The new drugs also help to shorten treatment time in patients who respond quickly to them.

 

“Two decades ago the cure rate for hepatitis C genotype 1 patients was about 6 percent, so this is a 10 times increase”

 

Dr. Monsour was one of the physicians involved in the Victrelis and Incivek clinical trials. In this new treatment for hepatitis C video, he notes how Victrelis has helped to double the cure rate for African-Americans with hepatitis C.

 

The new FDA-approved drugs offer more hope in fighting hepatitis C than ever before. However, some patients with severe liver damage who don’t respond effectively to antiviral medications may need a liver transplant to regain better health. The state-of-the-art Methodist Center for Liver Disease and Transplantation has experienced, compassionate physicians and staff and exceptional resources to help guide patients through its liver transplant program. Methodist is committed to leading-edge treatment with a focus on quality of life.

 

According to the Centers for Disease Control and Prevention, about 3.2 million people in the United States have chronic hepatitis C infection. Hepatitis C usually produces no signs or symptoms in early stages, and liver damage typically occurs decades later. People can get hepatitis C through exposure to blood infected with the virus, such as by sharing a needle or from an unsterilized tattoo or piercing. If you think you may be at risk for hepatitis C, talk with your Methodist Hospital in Houston doctor about having a blood test that can detect the virus.

 

 

Contacts

 

The Methodist Hospital in Houston

Ami Brezina, 832-667-5825

Marketing

www.methodisthealth.com

 

Trix